Skip to main content
. 2023 Nov 24;23:1140. doi: 10.1186/s12885-023-11608-5

Table 2.

Comparison of short-term efficacy between the two groups

Groups Total Cases CR PR SD PD ORR
Cases(%) Cases(%) Cases(%) Cases(%) Cases(%)
Nimotuzumab group 52 48(92.3) 4(7.7) 0 0 52(100.0)
Control group 57 45(78.9) 11(19.3) 1(1.8) 0 56(98.2)
χ2value 3.876 3.086 0.000 - 0.000
P value 0.049 0.079 1.000 - 1.000